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Abstract
Objectives: We analyzed clinical progression among persons diagnosed with HIV at the time of an AIDS-defining event, and
assessed the impact on outcome of timing of combined antiretroviral treatment (cART).
Methods: Retrospective, European and Canadian multicohort study.. Patients were diagnosed with HIV from 1997–2004 and
had clinical AIDS from 30 days before to 14 days after diagnosis. Clinical progression (new AIDS event, death) was described
using Kaplan-Meier analysis stratifying by type of AIDS event. Factors associated with progression were identified with
multivariable Cox regression. Progression rates were compared between those starting early (,30 days after AIDS event) or
deferred (30–270 days after AIDS event) cART.
Results: The median (interquartile range) CD4 count and viral load (VL) at diagnosis of the 584 patients were 42 (16, 119)
cells/mL and 5.2 (4.5, 5.7) log10 copies/mL. Clinical progression was observed in 165 (28.3%) patients. Older age, a higher VL
at diagnosis, and a diagnosis of non-Hodgkin lymphoma (NHL) (vs. other AIDS events) were independently associated with
disease progression. Of 366 patients with an opportunistic infection, 178 (48.6%) received early cART. There was no
significant difference in clinical progression between those initiating cART early and those deferring treatment (adjusted
hazard ratio 1.32 [95% confidence interval 0.87, 2.00], p = 0.20).
Conclusions: Older patients and patients with high VL or NHL at diagnosis had a worse outcome. Our data suggest that
earlier initiation of cART may be beneficial among HIV-infected patients diagnosed with clinical AIDS in our setting.
Citation: Miro JM, Manzardo C, Mussini C, Johnson M, d’Arminio Monforte A, et al. (2011) Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-
Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. PLoS ONE 6(10): e26009. doi:10.1371/journal.pone.0026009
Editor: Mark Wainberg, McGill University AIDS Centre, Canada
Received July 27, 2011; Accepted September 15, 2011; Published October 17, 2011
Copyright:  2011 Miro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by Istituto Superiore di Sanita`, VI Programma Nazionale di ricerca sull’AIDS 2006, Italy, Projects: ‘‘Eziopatogenesi,
studi immunologici e virologici dell’HIV/AIDS’’ - Grant: 40G.43 (Mussini), ‘‘Ricerca clinica e terapia della malattia da HIV’’ - Grant 30G.3 (Antinori), by the ‘‘Fundacio´n
Ma´ximo Soriano Jime´nez’’ (Barcelona, Spain) and the ‘‘Red Tema´tica Cooperativa de Grupos de Investigacio´n en Sida del Fondo de Investigacio´n Sanitaria (FIS),’’
and grant ISCIII-RETIC RD06/006 from the Instituto de Salud Carlos III, Madrid (Spain)(Manzardo, Miro). Dr. Miro´ was a recipient of an INT10/219 Intensification
Research Grant (I3SNS & PRICS programs) from the ‘‘Instituto de Salud Carlos III, Madrid (Spain)’’ and the ‘‘Departament de Salut de la Generalitat de Catalunya,
Barcelona (Spain)’’. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jmmiro@ub.edu
. These authors contributed equally to this work.
Introduction
Despite the fact that combined antiretroviral treatment (cART)
has made it possible to control HIV infection and extend survival if
started with a CD4+ cell count above 200 cells/mm3 [1]–[2], a
considerable proportion of patients still present with an AIDS-
defining condition at diagnosis [3]–[8]. Following treatment
guidelines, these patients should start cART. For AIDS-defining
conditions that do not have a specific treatment, such as progressive
multifocal leukoencephalopathy (PML) or cryptosporidiosis, cART
should be started as soon as possible. However, for AIDS-defining
conditions that do have a specific treatment, the possibility of
overlapping toxicities and pharmacokinetic/pharmacodynamic
interactions between cART and other drugs, and the possibility of
developing inflammatory immune reconstitution syndrome (IRIS)
[9]–[10], make it difficult to decide whether to start cART
immediately or defer it until the patient’s condition stabilizes [11].
The timing of cART in this case has not been well established, and
current guidelines are based on observational studies and expert
opinion.
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The ACTG A5164 trial [12] demonstrated that early cART
resulted in less rapid AIDS progression and death than deferred
cART. However, as 75% of the study sample had Pneumocystis
jiroveci pneumonia (PCP) and bacterial infections, these results may
not be valid for patients with other OIs or AIDS-defining
conditions that were underrepresented in this study or for patients
with tuberculosis, who were excluded. In addition, as the health-
care systems function differently in resource-limited settings, the
results of trials conducted in these settings may not be applicable to
other settings, and contradictory results may be obtained. For
example, in patients with cryptococcal meningitis, early cART
reduced mortality in the ACTG trial [12] but was deleterious in a
trial performed in Zimbabwe [13]. Regarding tuberculosis (TB),
randomized clinical trials (RCTs) conducted in resource-limited
settings [14]–[17] suggest that early cART (initiated during the
first 15 days) may lead to benefit among HIV-infected, cART-
naı¨ve patients with TB, at least for those with the greatest level of
immunosuppression (baseline CD4+ T cells ,50 cells/mm3). As
RCTs of the timing of cART in patients with OIs are likely to be
infeasible in developed countries because of the low incidence of
OIs, observational data from different clinical settings in Western
countries may provide insight as to whether it is possible to
extrapolate the information obtained from RCTs conducted in
resource-limited countries and may help physicians to improve the
clinical management of advanced patients.
The aims of this study were to analyze clinical progression and
survival among persons diagnosed with HIV infection at the time
of an AIDS-defining event and to assess the outcome of timing of
cART (early versus deferred) in these individuals in eight cohorts
from Europe and Canada.
Methods
This is a retrospective, multinational, multicohort study. We
pooled data on patients newly diagnosed with HIV presenting with
a clinical AIDS-defining event from 1997 to 2004 at the following
centers: Clinic of Infectious Diseases, Modena, Italy; Department of
Infectious Diseases, Ferrara, Italy; Clinic of Infectious Diseases,
Milan, Italy; Infectious Diseases Department, San Raffaele
Hospital, Milan (HSR), Italy; INMI Spallanzani, Rome, Italy;
Infectious Diseases Service, Hospital Clinic – IDIBAPS, University
of Barcelona, Barcelona, Spain; the Ian Charleson Centre, Royal
Free Hospital, London, UK; Southern Alberta Clinic, Calgary,
Canada. This study was approved by Institutional Review Boards
(IRBs) of all the above listed hospitals and IRBs specifically
approved the use of data without the informed consent of the
subjects, since data were analyzed retrospectively and anonymously.
Eligible patients from each cohort were those who had an AIDS
diagnosis (defined using the Centers for Disease Control and
Prevention (CDC) criteria) from 30 days before until 14 days after
their first positive HIV test. All AIDS-defining events occurring
during this period were considered to be events that occurred at
the time of diagnosis; any AIDS-defining event that occurred more
than 14 days after HIV diagnosis was considered to be a
subsequent event. Datasets were requested in a common format
and included demographic data (date of birth, sex, and risk group),
clinical events (dates and type of all AIDS events, date of death,
and date of HIV diagnosis), laboratory measurements at diagnosis
and during follow-up (CD4 cell counts and percentages, CD8 cell
counts and percentages, HIV RNA levels and haemoglobin), and
information on antiretroviral use (dates of starting and stopping all
antiretroviral drugs).
Early cART was defined as treatment started within the first 30
days after the diagnosis of the AIDS-defining condition; deferred
cART was defined as treatment started between days 31 and 270
days after diagnosis of the AIDS-defining condition. The choice of
30 days as cut off was made a priori and based on our clinical
experience as well as on results of several randomized clinical trials
(e.g. in the ACTG A5164 study [12] patients in the deferred arm
started cART from 28–244 days after diagnosis). Patients who died
or were lost to follow-up between day 0 and day 30 after diagnosis
of their AIDS-defining condition were excluded from the analysis,
regardless of when cART was initiated; patients dying between
days 31 and 270 without starting cART were assigned to the
deferred group. For analysis purposes, AIDS-defining events were
categorized as tuberculosis (TB), PCP, Kaposi’s sarcoma (KS),
non-Hodgkins lymphoma (NHL), and other OIs. Clinical
progression was defined as a new AIDS-defining event or death
(combined endpoint).
Statistical analysis
Patient follow-up was counted from the date of HIV diagnosis
until the date of the first new AIDS event (more than 14 days after
diagnosis) or death, whichever occurred first. Follow-up on
patients who remained alive and without a new AIDS event at
the end of the study period was right-censored on the date of the
patient’s last CD4 count or HIV viral load, whichever was latest.
Kaplan-Meier plots were used to describe progression rates among
all patients after stratifying by the type of AIDS event that was
present (see previous section). Factors associated with clinical
progression were identified using univariable and multivariable
Cox proportional hazards regression models. Factors were
considered to be statistically significant if p,0.05.
Clinical progression rates were compared in the early and
deferred cART groups using a similar approach. These analyses
were restricted to the 366 patients presenting with an opportunistic
infection who could be classified into one of these two groups.
Follow-up for these analyses again started at the time of HIV
diagnosis, with adjustment for sex, risk group, age, CD4 count and
viral load at diagnosis. Analyses were repeated considering
progression to death alone, and among the subgroups of patients
presenting with PCP and TB.
Results
Analyses of clinical progression according to type of AIDS
event
A total of 584 patients were included in these analyses. Table 1
shows selected characteristics of the study patients overall and
stratified by AIDS-defining event. Of the 584 patients, 96 (16.4%)
were known to have died, 110 (18.8%) experienced a new AIDS
event, and 165 (28.3%) experienced the combined clinical
progression endpoint (new AIDS event or death). Figure 1 shows
the proportion of patients experiencing clinical progression and
dying both overall and stratified by initial AIDS-defining event.
Overall, progression rates at 3, 6, 9, and 12 months were 20.3%,
24.4%, 27.3%, and 28.8%; mortality rates at the same timepoints
were 9.5%, 12.5%, 13.6% and 14.4%, respectively. Of note,
almost all patients who experienced clinical progression or death
did so during the first year of follow-up, with patients with a
diagnosis of NHL at baseline having a particularly poor prognosis.
Unadjusted analyses (Table 2, left-hand column) confirmed the
poorer prognosis among those with NHL, with these individuals
being more than twice as likely to experience clinical progression
(relative hazard [RH] 2.38 [95% confidence interval 1.08, 5.23],
p = 0.03) than individuals with other AIDS diagnoses. Other
factors associated with a poorer prognosis were older age (RH per
5 years older: 1.14 [1.06, 1.22], p = 0.0003) and a higher viral load
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at diagnosis (RH per log2 increment: 1.32 [1.10, 1.58], p = 0.002).
The poorer prognosis among those with NHL remained after
adjustment for age and viral load (Table 2, right-hand column).
Results of analyses of mortality reached similar conclusions. In
unadjusted analyses, patients with a diagnosis of NHL were over
four times as likely to die than patients with other AIDS events
(RH: 4.23 [1.86, 9.57], p = 0.0006); this association remained
(adjusted RH: 9.15 [3.31, 25.31], p = 0.0001) after adjusting for
the patient’s age and viral load at the time of diagnosis.
Analyses of clinical progression according to timing of
treatment
Of the 584 patients, 159 were not included in these analyses
because they did not have sufficient follow-up or data (25 were lost
to follow-up between day 0 and 30, 104 had insufficient follow-up
to be classified and 30 could not be categorized into one of
treatment arms for other reasons). An additional seven patients
died within the first 30 days, leaving 418 patients who met the
criteria previously defined. Overall, those who were excluded were
more likely to be from the injecting drug users group (21% of those
excluded vs. 10% of those included) or ‘Other’ (40% vs. 32%) risk
groups and were correspondingly less likely to be from the
homosexual (10% vs. 24%) risk group (p = 0.0001). Excluded
patients were more likely to come from Spain (50% vs. 22%) and
less likely to come from the other participating countries
(p = 0.0001). Finally, largely as a result of the differences in risk
groups, those excluded were more likely to be female (29% vs.
21%, p = 0.07). Baseline age, CD4 T- cells count and plasma HIV
RNA levels did not differ significantly between excluded and
included patients.
Of the 418 patients, 366 had presented with an opportunistic
infection and were included in the analysis: 178 (48.6%) received
early treatment and 185 (50.5%) received deferred treatment
(Table 3). Only three patients (0.8%) never started cART. A total
of 75 (20.5%) patients developed a new AIDS event and 18 (4.9%)
died, with 90 (24.6%) experiencing clinical progression.
Table 3 shows the characteristics of these patients, overall and
stratified by early or deferred treatment. The median time for
starting cART in the early treatment and deferred treatment
groups was 14 (IQR: 4, 22) and 49 (IQR: 39, 71) days,
respectively. Overall, the characteristics of patients receiving early
and deferred treatment were broadly similar with the exception of
some differences by country. There were no significant differences
between the treatment regimens in the two groups.
In unadjusted analysis, patients who deferred treatment were
32% more likely to progress to a new AIDS event or die than those
Table 1. Patient characteristics, overall and stratified by type of AIDS-defining event*; entries are n (%) unless otherwise stated.
All patients TB PCP KS NHL Other OIs**
N (% of total) 584 143 216 50 15 199
Male sex 446 (76.5) 101 (71.1) 168 (77.8) 46 (92.0) 12 (80.0) 150 (75.4)
Risk group IDU 77 (13.2) 32 (22.4) 22 (10.2) 0 (-) 0 (-) 20 (10.1)
Homosexual 118 (20.2) 12 (8.4) 63 (29.2) 17 (34.0) 2 (13.3) 42 (21.1)
Heterosexual 190 (32.5) 61 (42.7) 75 (34.7) 13 (26.0) 5 (33.3) 57 (28.6)
Other 199 (34.1) 38 (26.6) 56 (25.9) 20 (40.0) 8 (53.3) 80 (40.2)
Days from AIDS to HIV diagnosis Median (IQR) 0 (22, 2) 0 (21, 6) 0 (22, 1) 0 (23, 0) 0 (25, 0) 0 (21, 0)
Age at diagnosis (years) Median (IQR) 39 (33, 48) 37 (31, 43) 39 (34, 47) 48 (34, 54) 40 (39, 49) 40 (34, 51)
CD4 count at diagnosis (cells/mm3) Median (IQR) 40 (14, 109) 81 (25, 177) 27 (11, 68) 84 (15, 231) 109 (66, 195) 27 (10, 78)
HIV RNA at diagnosis (log10 cp/ml) Median (IQR) 5.3 (4.6, 5.7) 5.4 (4.9, 5.9) 5.2 (4.5, 5.6) 5.4 (4.5, 5.7) 5.0 (4.4, 5.4) 5.2 (4.6, 5.7)
Country of origin Italy 222 (38.0) 36 (25.2) 80 (37.0) 27 (54.0) 8 (53.3) 77 (38.7)
Spain 175 (30.0) 58 (40.6) 53 (24.5) 7 (14.0) 0 (-) 64 (32.2)
UK 132 (22.6) 45 (31.5) 49 (22.7) 13 (26.0) 4 (26.7) 38 (19.1)
Canada 55 (9.4) 4 (2.8) 34 (15.7) 3 (6.0) 3 (20.0) 20 (10.1)
Started cART 477 (81.7) 115 (80.4) 179 (82.9) 47 (94.0) 13 (86.7) 160 (80.4)
Days to start of cART Median (IQR) 31 (13, 53) 42 (18, 79) 30 (15, 43) 18 (1, 37) 44 (21, 61) 27 (10, 49)
Timing of cART*** Immediate 211 (50.5) 39 (41.9) 85 (50.0) 30 (69.8) 3 (30.0) 72 (51.4)
Deferred 207 (49.5) 54 (58.1) 85 (50.0) 13 (30.2) 7 (70.0) 68 (48.6)
Type of cART NNRTI-based 137 (28.7) 44 (38.3) 47 (26.3) 12 (25.5) 4 (30.8) 46 (28.8)
PI-based 297 (62.3) 54 (47.0) 124 (69.3) 32 (68.1) 9 (69.2) 95 (59.4)
Other 43 (9.0) 17 (14.8) 8 (4.5) 3 (6.4) 0 (-) 19 (11.9)
Total follow-up (years) Median (IQR) 1.5 (0.2, 3.4) 1.4 (0.2, 3.5) 1.6 (0.4, 3.5) 2.0 (0.9, 3.9) 0.4 (0.0, 0.7) 1.3 (0.1, 3.3)
New AIDS event within first year1 110 (18.8) 31 (21.7) 36 (16.7) 18 (36.0) 3 (20.0) 39 (19.6)
Death within first year1 70 (12.0) 9 (6.3) 22 (10.2) 3 (6.0) 7 (46.7) 28 (14.1)
*As patients may have experienced more than one of the specific AIDS-defining events, each event is treated as a separate binary covariate.
**Included the following events: oesophageal candidiasis (n = 75); toxoplasmosis (n = 50); cytomegalovirus (n = 36); cryptococcal meningitis (n = 19); cryptosporidiosis
(n = 8); progressive multifocal leukoencephalopathy (n = 18), herpes simplex infections (n = 10).
***Based on patients with sufficient follow-up to be categorized into one of the two groups (see Methods).
1A small number of patients developed AIDS-defining conditions or died that did not fall into one of the five specific categories (e.g. wasting syndrome) – these patients
are included in the total column but will not be in the subcolumns.
doi:10.1371/journal.pone.0026009.t001
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Figure 1. Kaplan-Meier plot of the cumulative proportion of patients experiencing (i) clinical progression and (ii) death, according
to the AIDS diagnosis present at HIV diagnosis*. * As patients may have had more than one AIDS-defining condition at the time of diagnosis,
they may fall into more than one of the groups in the figure.
doi:10.1371/journal.pone.0026009.g001
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Table 2. Factors associated with clinical progression (a new AIDS event or death) (N = 584).
Univariable models Multivariable model
RH 95% CI p-value RH 95% CI p-value
AIDS diagnosis*
TB vs. no TB 1.00 (0.67, 1.49) 0.99 1.17 (0.73, 1.86) 0.51
PCP vs. no PCP 0.83 (0.58, 1.18) 0.29 0.94 (0.63, 1.41) 0.77
KS vs. no KS 1.12 (0.66, 1.88) 0.68 1.32 (0.77, 2.26) 0.32
NHL vs. no NHL 2.38 (1.08, 5.23) 0.03 2.84 (1.11, 7.23) 0.03
Female 1.06 (0.74, 1.53) 0.75 - - -
Risk group
Heterosexual 1 - - - - -
Homosexual 0.63 (0.39, 1.01) 0.06 - - -
IDU 1.15 (0.71, 1.86) 0.56 - - -
Other 1.20 (0.83, 1.73) 0.34 - - -
Age at diagnosis (/5 years older) 1.14 (1.06, 1.22) 0.0003 1.12 (1.03, 1.21) 0.007
CD4 count at diagnosis (/50 cells/mm3 higher) 0.96 (0.90, 1.03) 0.24 - - -
Viral load at diagnosis (/log10 higher) 1.32 (1.10, 1.58) 0.002 1.34 (1.12, 1.60) 0.001
*As patients may have experienced more than one of the specific AIDS-defining events, each event is treated as a separate binary covariate; therefore, patients with the
event of interest are compared to those without that event (but who will have at least one of the other AIDS events).
doi:10.1371/journal.pone.0026009.t002
Table 3. Patient characteristics, overall and stratified by timing of cART (early versus deferred); entries are n (%) unless otherwise
stated.
All patients Timing of cART
Early Deferred p-value
N (% of total) 366 (100.0) 178 (48.6) 188 (51.4)
Male sex 282 (77.3) 132 (74.6) 150 (79.8) 0.29
Risk group IDU 43 (11.8) 18 (10.1) 25 (13.3)
Homosexual 83 (22.7) 37 (20.8) 46 (24.5)
Heterosexual 125 (34.2) 65 (36.5) 60 (31.9)
Other 115 (31.4) 58 (32.6) 57 (30.3) 0.56
Age (years) Median (IQR) 39 (33, 46) 39 (33, 48) 38 (33, 43) 0.14
CD4 count at diagnosis (cells/mm3) Median (IQR) 34 (13, 98) 32 (12, 103) 34 (16, 92) 0.73
HIV RNA at diagnosis (log10 copies/ml) Median (IQR) 5.2 (4.6, 5.7) 5.2 (4.4, 5.7) 5.3 (4.8, 5.7) 0.18
Country of origin Italy 138 (37.7) 78 (43.8) 60 (31.9)
Spain 89 (24.3) 39 (21.9) 50 (26.6)
UK 97 (26.5) 51 (28.7) 46 (24.5)
Canada 42 (11.5) 10 (5.6) 32 (17.0) 0.002
Type of AIDS event TB 93 (25.4) 39 (21.9) 54 (28.7) 0.17
PCP 158 (43.2) 75 (42.1) 83 (44.2) 0.78
Other* 135 (36.9) 68 (38.2) 67 (35.6) 0.69
Days to start of cART 31 (14, 49) 14 (4, 22) 49 (39, 71) 0.0001
Type of cART
NNRTI-based 102 (28.1) 44 (24.7) 58 (31.4)
PI-based 226 (62.3) 117 (65.7) 109 (58.9)
Other 35 (9.6) 17 (9.6) 18 (9.7)
No cART 3 (0.8) - 3 (1.6) 0.35
Total follow-up (years) Median (IQR) 2.2 (0.9, 4.1) 2.4 (0.8, 4.0) 2.1 (1.0, 4.5) 0.85
*Included the following events: oesophageal candidiasis (n = 59); toxoplasmosis (n = 29); cytomegalovirus (n = 23); cryptococcal meningitis (n = 15); cryptosporidiosis
(n = 7); progressive multifocal leukoencephalopathy (n = 5), herpes simplex infections (n = 8).
doi:10.1371/journal.pone.0026009.t003
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initiating treatment early, although this finding was not statistically
significant (unadjusted RH 1.32 [0.87, 2.00], p = 0.20); this effect
was unchanged (adjusted RH 1.39 [0.90, 2.15], p = 0.14) after
controlling for other clinical and demographic characteristics at
baseline (sex, risk group, age, CD4 count and viral load at
diagnosis). Analyses of progression to death alone reached similar
conclusions (unadjusted RH: 1.37 [0.71, 2.65], p = 0.34; adjusted
RH: 1.59 [0.77, 3.28], p = 0.21) although as patients who died in
the first 30 days after diagnosis (n = 7) were excluded from these
analyses, these findings should be interpreted cautiously.
In the subgroup of patients presenting with PCP only (n = 152;
74 (48.7%) early treatment), 31 (20.4%) patients experienced
clinical progression. As before, patients who deferred treatment
were more likely to experience clinical progression, although
differences were not significant, either before or after adjustment
for potential confounders (unadjusted RH: 1.68 [0.80, 3.51],
p = 0.17; adjusted RH: 1.90 [0.90, 4.03], p = 0.09). In the
subgroup of patients presenting with TB only (n = 104; 51
(49.0%) early treatment), 27 (26.0%) patients experienced clinical
progression. Again, patients who deferred treatment were more
likely to experience clinical progression, with differences reaching
statistical significance after adjustment for potential confounders
(unadjusted RH: 2.00 [0.90, 4.47], p = 0.09; adjusted RH 2.55
[1.10, 5.94], p = 0.03). On the other hand, 47 patients had more
than one AIDS-defining opportunistic infection at the time of
diagnosis (two: n = 44; three: n = 3). There were no association
between having multiple events and clinical progression (adjusted
RH 1.38 [0.78, 2.44], p = 0.27).
Finally, there was no evidence that clinical progression changed
over time (RH [95%CI] per later year: 0.97 [0.87, 1.09], p = 0.64)
and there was no evidence of any interaction between the
treatment effect and the calendar year (p = 0.87).
Discussion
A considerable proportion of patients continue to present with a
CDC category C event at diagnosis of HIV infection either in
developed or in developing countries. As the optimal timing for
starting cART in this clinical setting has not been well-established,
several recent clinical trials [12]–[16] have attempted to clarify this
important issue. Our study is based on observational data collected
before the publication of these results. Concerns about pharma-
cokinetic and pharmacodynamic interactions and overlapping
toxicities between antiretrovirals and antimicrobial drugs used for
treating OIs and the possibility of immune reconstitution
syndrome meant that in clinical practice many clinicians preferred
to defer cART [11]–[18]. However, recently published data
suggests that early cART is crucial for optimal prognosis in
patients presenting with an AIDS-defining opportunistic infection
[12]–[16]. Data from the ACTG A5164 [12] study suggest that,
globally, for fungal infections and/or CD4+ T-cell count lower
than 50 cells/mL, an early initiation of cART (median 12 days)
significantly reduces risk for disease progression and death
compared with a later start of cART (median 45 days), indicating
that even a few weeks of earlier cART could be beneficial in
antiretroviral-naı¨ve, HIV-infected individuals diagnosed with
these opportunistic infections. Authors of this ACTG trial admit
a possible selection bias in their study, since patients ‘not ideal’ for
a RCT, such as active injecting drug users (IDUs) or patients with
very severe infections may have been excluded. A post-hoc
analysis of the ACTG A5164 study showed a trend towards a
better outcome for patients presenting with PCP starting cART in
the early treatment arm, although statistical significance was not
reached (p.0.05). Similarly, in our study, patients with PCP who
deferred treatment were 90% more likely to progress to a new
AIDS event or die than those initiating treatment in the first 30
days after diagnosis, although the difference between the two
groups did not reach statistical significance (p = 0.09 in the
adjusted analysis).
TB is the second most common OI in some European settings
and the most common one worldwide. The RCTs on timing of
cART in the context of HIV-TB co-infection have been conducted
in research-poor settings [14]–[17], whereas in Western countries
only observational data are available [18]. The SAPIT study [14]
determined that antiretroviral treatment should be started during
the intensive phase or maintenance phase of tuberculosis treatment
in patients with pulmonary TB and should not be delayed until after
the completion of the latter, at least for patients with CD4+ T-cells
counts equal to or lower than 500 cells/mL. A sub-study from this
trial [15], presented at the 2011 CROI concluded that among
patients with pulmonary TB with a CD4 T-cell count,50 cells/mL,
cART initiation within 4 weeks was associated with improved
AIDS-free survival, but a higher risk of IRIS; for patients with a
CD4+ T-cell count .50 cells/mm3 earlier cART initiation was
associated with a reduction in the risk of IRIS without compromis-
ing AIDS-free survival. As yet unpublished data from the
CAMELIA [16] and ACTG 5221 STRIDE [17] studies also
confirms that for individuals with severe immunosuppression
(CD4+ T cells count ,50 cells/mm3), early cART (within 2 weeks)
significantly reduced the risk of disease progression and death. In
our study, the median (IQR) CD4 T cell count for patients co-
infected with TB was 81 cells/mL (25–177). In this sub-group,
starting cART 30 days after diagnosis carried a significantly higher
probability of disease progression or death compared with patients
starting cART earlier (adjusted HR 2.55 [1.10, 5.94], p = 0.03).
One of the limitations of our study was that we did not know
whether the patients presented pulmonary or extra-pulmonary
forms of TB. Based on data from the Euro HIV/TB study [19], the
prevalence of extra-pulmonary TB in Central/Northern Europe
and Southern Europe was 73.8% and 61.9%, respectively.
Therefore, most cases from our cohort very probably had extra-
pulmonary TB. This is an important issue because of more than
90% of patients included in the three RCTs stated above had
pulmonary TB [14]–[17]. For this reason, it would be desirable to
have more data regarding the best timing of cART for extra-
pulmonary TB in both developed and developing countries [20].
In this way, the clinical scenario is more complex in central
nervous system opportunistic infections where early initiation of
cART does not always reduce mortality. One randomized trial in
Zimbabwe [13] compared the outcome of 54 patients diagnosed
with cryptococcal meningitis and treated with fluconazole
monotherapy and concluded that early cART was detrimental
in this patient group (88% mortality rate in patients treated in the
first 72 hours vs. 54% in patients who deferred cART for 4 weeks,
P, 0.006). In a randomized trial performed in Vietnam [21],
early cART (within 2 weeks) did not confer a survival benefit in
patients with TB meningitis. Therefore, when the OI (at least
cryptococcal and TB) involves the central nervous system early
cART could prove an exception in this clinical context; however,
these results cannot be extended to resource-rich settings (e.g. early
cART reduced mortality in patients with cryptococcal meningitis
included in the ACTG trial [12]), and more controlled data are
needed in order to confirm them. We did not have information
regarding the number of cases of TB meningitis in our European
and Canadian cohorts. However, the proportion is probably low.
In one study performed in Spain in the pre-cART era, less than
10% of TB cases in HIV-infected patients had central nervous
system involvement [22].
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Our study shows a trend towards a better outcome for patients
presenting with an AIDS-defining condition at diagnosis of HIV
infection who started cART in the first 30 days from diagnosis. For
OIs other than PCP and TB, a trend towards a better outcome in
patients starting cART in the first 30 days was also observed,
although specific conclusions can’t be reached because of limited
sample size and because of the heterogeneity of conditions
(including oesophageal candidiasis, toxoplasmosis, cytomegalovi-
rus, cryptococcal meningitis, cryptosporidiosis, progressive multi-
focal leukoencephalopathy, and herpes simplex infections) that
were seen in this group.
Timing of cART has been shown to differ by country (Canada
started later, Italy earlier) and by type of AIDS-defining event (in
patients presenting with KS, cART was started earlier than in
other conditions). cART regimens also were broadly similar in the
early and the deferred arms, with some differences depending on
type of OI. In our study, the factors independently associated with
disease progression and death were a diagnosis of NHL, older age,
and a higher viral load at diagnosis. Prognosis was independent of
CD4 count stratum, most likely reflecting the universally low CD4
counts in these patients. Of note, where clinical events occurred,
they were generally observed in the first 48 weeks of follow-up,
suggesting that patients who do not experience clinical progression
during this period are likely to have a good subsequent prognosis.
Survival analysis showed that patients diagnosed with NHL had
the worst prognosis.
Limitations
Our study has some limitations by the fact that it is a
retrospective cohort study and the information at the time of
AIDS diagnosis (particularly CD4 count and VL) may sometimes
be missing. Despite the large sample size, the number of patients
with some AIDS-defining cancers (e.g. KS and NHL) remains low,
limiting any conclusions that can be drawn relating to the timing
of cART in patients with cancer. As a result, we were unable to
perform sub-analyses of OIs other than PCP and tuberculosis.
Furthermore, as information was not available on the location of
tuberculosis, we were unable to consider tuberculosis meningitis as
a specific condition. As this is an observational study, we cannot
rule out the possibility of unmeasured confounders (e.g. bias by
clinical indication); it is possible that any differences seen between
those in the early and deferred cART groups may reflect other
unmeasured differences between these patients. Of note, the seven
patients who died rapidly were excluded from our analyses; thus,
our conclusions are applicable only to those who survive for at
least 30 days after HIV diagnosis. Finally, cause of death and
reasons for never starting cART remain unknown in some
patients.
Conclusions
In conclusion, the results of our cohort study are consistent with
data emerging from randomized clinical trials [12–14,15] and
suggest an earlier start for cART among HIV-infected patients
diagnosed with an OI-defining event. Patients with PCP at
baseline tended to have a better outcome when cART was started
earlier. Among individuals with TB, people deferring cART for
more than 30 days after diagnosis of their OI had twice the risk of
clinical progression or death than those who initiated cART
immediately. Since almost all randomized clinical trials for timing
of cART were conducted in resource-limited settings, more
controlled data are needed to establish the best timing for starting
cART in patients presenting with AIDS-defining OI in developed
countries, where access to cART and health-care systems function
differently.
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